Kyverna Therapeutics (KYTX)
Kyverna Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq.
9.5M
Short interest
settlement 2026-10-15
10.5
Days to cover
+1.6 days vs prior
59.0%
Short share of volume
2026-11-02
3,428
Fails to deliver
settlement 2026-10-13
Wed 11 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in KYTX is 9,543,350 shares, up 777,016 shares over the last month. Over the last 48 readings it ranged from 1,246,292 shares (15 July 2025) to 9,618,412 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 910K shares a day that is 10.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/kytx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 9,543,350 | -0.8% | 909,746 | 10.49 |
| 2026-09-30 | 9,618,412 | +9.7% | 1,086,231 | 8.85 |
| 2026-09-15 | 8,766,334 | +3.7% | 812,839 | 10.78 |
| 2026-08-31 | 8,454,341 | -0.5% | 684,634 | 12.35 |
| 2026-08-14 | 8,498,858 | +3.9% | 636,888 | 13.34 |
| 2026-07-31 | 8,177,359 | +4.2% | 937,117 | 8.73 |
| 2026-07-15 | 7,846,393 | +8.7% | 1,297,725 | 6.05 |
| 2026-06-30 | 7,218,911 | +18.9% | 1,583,444 | 4.56 |
| 2026-06-15 | 6,069,905 | +5.8% | 720,918 | 8.42 |
| 2026-05-29 | 5,739,106 | +8.6% | 837,754 | 6.85 |
| 2026-05-15 | 5,283,320 | +2.4% | 858,635 | 6.15 |
| 2026-04-30 | 5,161,190 | +22.0% | 1,726,596 | 2.99 |
| 2026-04-15 | 4,231,925 | +0.5% | 678,028 | 6.24 |
| 2026-03-31 | 4,212,602 | +0.2% | 683,757 | 6.16 |
| 2026-03-13 | 4,205,266 | +0.4% | 668,817 | 6.29 |
| 2026-02-27 | 4,189,784 | +6.8% | 439,931 | 9.52 |
| 2026-02-13 | 3,924,276 | +12.0% | 652,823 | 6.01 |
| 2026-01-30 | 3,505,050 | +2.8% | 984,496 | 3.56 |
| 2026-01-15 | 3,408,408 | -4.1% | 972,298 | 3.51 |
| 2025-12-31 | 3,553,051 | +1.8% | 3,004,805 | 1.18 |
| 2025-12-15 | 3,489,945 | -1.1% | 2,137,379 | 1.63 |
| 2025-11-28 | 3,530,429 | +13.5% | 555,489 | 6.36 |
| 2025-11-14 | 3,110,221 | +15.3% | 696,530 | 4.47 |
| 2025-10-31 | 2,696,732 | +71.0% | 741,905 | 3.63 |
| 2025-10-15 | 1,577,306 | +9.0% | 1,068,625 | 1.48 |
| 2025-09-30 | 1,447,317 | -10.0% | 614,237 | 2.36 |
| 2025-09-15 | 1,608,183 | +19.3% | 269,917 | 5.96 |
| 2025-08-29 | 1,348,351 | -14.5% | 275,428 | 4.90 |
| 2025-08-15 | 1,576,692 | +4.9% | 280,974 | 5.61 |
| 2025-07-31 | 1,502,423 | +20.6% | 217,781 | 6.90 |
| 2025-07-15 | 1,246,292 | -38.6% | 603,816 | 2.06 |
| 2025-06-30 | 2,029,913 | -3.3% | 739,393 | 2.75 |
| 2025-06-13 | 2,098,502 | +0.4% | 423,898 | 4.95 |
| 2025-05-30 | 2,090,942 | -18.9% | 528,389 | 3.96 |
| 2025-05-15 | 2,579,347 | +20.7% | 226,348 | 11.40 |
| 2025-04-30 | 2,136,619 | -19.4% | 219,209 | 9.75 |
| 2025-04-15 | 2,651,887 | -10.0% | 256,180 | 10.35 |
| 2025-03-31 | 2,945,611 | +2.7% | 360,477 | 8.17 |
| 2025-03-14 | 2,867,821 | -6.1% | 255,511 | 11.22 |
| 2025-02-28 | 3,053,409 | -0.6% | 267,220 | 11.43 |
| 2025-02-14 | 3,073,161 | +10.3% | 346,617 | 8.87 |
| 2025-01-31 | 2,785,433 | -2.8% | 566,492 | 4.92 |
| 2025-01-15 | 2,865,595 | -2.9% | 277,387 | 10.33 |
| 2024-12-31 | 2,950,537 | +14.0% | 370,830 | 7.96 |
| 2024-12-13 | 2,588,087 | +23.0% | 440,899 | 5.87 |
| 2024-11-29 | 2,103,959 | -9.2% | 353,345 | 5.95 |
| 2024-11-15 | 2,315,832 | -4.0% | 247,105 | 9.37 |
| 2024-10-31 | 2,412,408 | -3.3% | 231,667 | 10.41 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of KYTX volume is 59.0%, down 6.4 points over the last five sessions. Over the last 30 readings it ranged from 45.1% (21 October 2026) to 75.2% (28 October 2026). The latest reading is 3.0 points below the 30-session average of 62.1%, on 279K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 165K | 279K | 59.0% | 3,690 |
| 2026-10-30 | 170K | 262K | 64.7% | 528 |
| 2026-10-29 | 208K | 356K | 58.5% | 0 |
| 2026-10-28 | 263K | 350K | 75.2% | 70 |
| 2026-10-27 | 250K | 428K | 58.3% | 566 |
| 2026-10-26 | 238K | 363K | 65.4% | 929 |
| 2026-10-23 | 227K | 411K | 55.1% | 14,190 |
| 2026-10-22 | 98K | 183K | 53.6% | 0 |
| 2026-10-21 | 190K | 422K | 45.1% | 10,804 |
| 2026-10-20 | 167K | 342K | 48.7% | 325 |
| 2026-10-19 | 194K | 318K | 60.9% | 99 |
| 2026-10-16 | 175K | 313K | 55.9% | 4,631 |
| 2026-10-15 | 280K | 374K | 75.0% | 2,073 |
| 2026-10-14 | 300K | 453K | 66.2% | 267 |
| 2026-10-13 | 332K | 520K | 63.9% | 9,347 |
| 2026-10-12 | 116K | 181K | 64.2% | 324 |
| 2026-10-09 | 233K | 367K | 63.5% | 4,485 |
| 2026-10-08 | 288K | 466K | 61.6% | 28,042 |
| 2026-10-07 | 222K | 309K | 71.7% | 0 |
| 2026-10-06 | 210K | 345K | 60.7% | 18,204 |
| 2026-10-05 | 247K | 412K | 59.8% | 34 |
| 2026-10-02 | 347K | 614K | 56.6% | 10 |
| 2026-10-01 | 184K | 319K | 57.5% | 0 |
| 2026-09-30 | 160K | 262K | 61.2% | 3,776 |
| 2026-09-29 | 229K | 360K | 63.4% | 68 |
| 2026-09-28 | 272K | 419K | 65.0% | 356 |
| 2026-09-25 | 451K | 640K | 70.5% | 50 |
| 2026-09-24 | 1.1M | 1.5M | 73.5% | 5,173 |
| 2026-09-23 | 200K | 284K | 70.6% | 0 |
| 2026-09-22 | 204K | 358K | 56.8% | 98 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in KYTX is 3,428 shares, down 1,382 shares over the last settlement date. Over the last 30 readings it ranged from 10 shares (17 August 2026) to 151,867 shares (1 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 3,428 | $6.21 | $21K |
| 2026-09-30 | 4,810 | $6.84 | $33K |
| 2026-09-29 | 1,780 | $6.82 | $12K |
| 2026-09-23 | 184 | $7.51 | $1K |
| 2026-09-15 | 2,115 | $7.40 | $16K |
| 2026-09-10 | 1,360 | $7.64 | $10K |
| 2026-09-03 | 10,660 | $8.62 | $92K |
| 2026-09-02 | 16,927 | $8.35 | $141K |
| 2026-08-25 | 4,762 | $8.24 | $39K |
| 2026-08-19 | 38,737 | $8.50 | $329K |
| 2026-08-17 | 10 | $8.17 | $82 |
| 2026-08-13 | 51 | $8.05 | $411 |
| 2026-08-12 | 48,700 | $8.02 | $391K |
| 2026-08-05 | 20,693 | $7.78 | $161K |
| 2026-08-04 | 701 | $7.51 | $5K |
| 2026-08-03 | 2,845 | $7.30 | $21K |
| 2026-07-24 | 55 | $7.29 | $401 |
| 2026-07-01 | 151,867 | $8.91 | $1.4M |
| 2026-06-29 | 35,469 | $8.44 | $299K |
| 2026-06-26 | 26,700 | $8.20 | $219K |
| 2026-06-22 | 2,699 | $8.07 | $22K |
| 2026-06-15 | 1,408 | $8.06 | $11K |
| 2026-06-12 | 2,382 | $7.87 | $19K |
| 2026-06-10 | 59 | $7.85 | $463 |
| 2026-06-09 | 293 | $7.71 | $2K |
| 2026-06-08 | 2,704 | $7.47 | $20K |
| 2026-06-05 | 14 | $7.95 | $111 |
| 2026-05-29 | 6,937 | $8.65 | $60K |
| 2026-04-28 | 21 | $8.99 | $189 |
| 2026-04-02 | 7,155 | $8.77 | $63K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for KYTX in the last 90 days. The most recent filings are listed below. Latest filing: SEIDENBERG BETH C (Director) on 2026-05-27.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | SEIDENBERG BETH C | Director | Grant | 5K | $0.00 | $0 | 22K |
| 2026-05-27 | Shaw Christi | Executive Chairperson | Tax withholding | 4K | $8.59 | $36K | 67K |
| 2026-05-27 | Cohen Fred E | Director | Grant | 5K | $0.00 | $0 | 22K |
| 2026-05-27 | CLARK IAN T | Director | Grant | 5K | $0.00 | $0 | 22K |
| 2026-05-27 | Aktar Mert | Director | Grant | 5K | $0.00 | $0 | 22K |
| 2026-03-13 | GRASSO MARC | Chief Financial Officer | Grant | 10K | $0.00 | $0 | 10K |
| 2026-03-13 | GEHCHAN NAJI | See Remarks | Grant | 18K | $0.00 | $0 | 18K |
| 2026-03-13 | Biddle Warner Weston | Chief Executive Officer | Grant | 58K | $0.00 | $0 | 58K |
| 2026-02-24 | Emany Sravan Kumar | Director | Grant | 11K | $0.00 | $0 | 11K |
| 2026-02-24 | Miller Andrew Craig | Director | Grant | 11K | $0.00 | $0 | 11K |
| 2026-01-12 | Shaw Christi | Executive Chairperson | Grant | 24K | $0.00 | $0 | 71K |
| 2026-01-12 | Shaw Christi | Executive Chairperson | Grant | 30K | $0.00 | $0 | 47K |
| 2025-12-18 | SEIDENBERG BETH C | Director | Buy | 133K | $7.50 | $1000K | 869K |
| 2025-12-18 | Westlake BioPartners Opportunity Fund I, L.P. | 10% owner | Buy | 133K | $7.50 | $1000K | 869K |
| 2025-12-15 | Walker Karen Marie | Chief Technology Officer | Sell | 24K | $12.20 | $293K | 23K |
| 2025-12-15 | Walker Karen Marie | Chief Technology Officer | Exercise or conversion | 24K | $4.83 | $116K | 47K |
| 2025-05-29 | Cohen Fred E | Director,TenPercentOwner | Grant | 17K | $0.00 | $0 | 17K |
| 2025-05-29 | CLARK IAN T | Director | Grant | 17K | $0.00 | $0 | 17K |
| 2025-05-29 | Aktar Mert | Director | Grant | 17K | $0.00 | $0 | 17K |
| 2025-05-29 | SPIEGELMAN DANIEL K | Director | Grant | 17K | $0.00 | $0 | 17K |
| 2025-05-29 | SEIDENBERG BETH C | Director,TenPercentOwner | Grant | 17K | $0.00 | $0 | 17K |
| 2025-05-29 | Shaw Christi | Director | Grant | 17K | $0.00 | $0 | 17K |
| 2025-04-11 | Walker Karen Marie | Chief Technology Officer | Grant | 13K | $0.00 | $0 | 23K |
| 2025-04-11 | Jones Ryan Alexander | Chief Financial Officer | Grant | 12K | $0.00 | $0 | 56K |
| 2024-06-06 | Walker Karen Marie | Chief Technology Officer | Exercise or conversion | 10K | $4.42 | $43K | 10K |
| 2024-05-28 | Jones Ryan Alexander | Chief Financial Officer | Exercise or conversion | 7K | $0.73 | $5K | 44K |
| 2024-05-28 | Jones Ryan Alexander | Chief Financial Officer | Exercise or conversion | 11K | $0.73 | $8K | 37K |
| 2024-02-12 | Northpond Ventures III GP, LLC | Other | Conversion | 2.8M | price not stated in the filing | not stated | 2.8M |
| 2024-02-12 | Northpond Ventures III GP, LLC | Other | Buy | 450K | $22.00 | $9.9M | 450K |
| 2024-02-12 | GILEAD SCIENCES, INC. | TenPercentOwner | Buy | 910K | $22.00 | $20.0M | 4.1M |
| 2024-02-12 | GILEAD SCIENCES, INC. | TenPercentOwner | Conversion | 3.2M | price not stated in the filing | not stated | 3.2M |
| 2024-02-12 | Bain Capital Life Sciences Fund III, L.P. | TenPercentOwner | Buy | 450K | $22.00 | $9.9M | 3.2M |
| 2024-02-12 | Bain Capital Life Sciences Fund III, L.P. | TenPercentOwner | Conversion | 2.7M | price not stated in the filing | not stated | 2.7M |
| 2024-02-12 | Westlake BioPartners GP I, LLC | TenPercentOwner | Conversion | 736K | price not stated in the filing | not stated | 736K |
| 2024-02-12 | Westlake BioPartners GP I, LLC | TenPercentOwner | Conversion | 3.8M | price not stated in the filing | not stated | 3.8M |
| 2024-02-12 | SEIDENBERG BETH C | Director,TenPercentOwner | Conversion | 736K | price not stated in the filing | not stated | 736K |
| 2024-02-12 | SEIDENBERG BETH C | Director,TenPercentOwner | Conversion | 3.8M | price not stated in the filing | not stated | 3.8M |
| 2024-02-12 | Cohen Fred E | Director,TenPercentOwner | Conversion | 4.5M | price not stated in the filing | not stated | 4.5M |
| 2024-02-12 | Vida Ventures GP III, L.L.C. | TenPercentOwner | Buy | 583 | $22.00 | $13K | 583 |
| 2024-02-12 | Vida Ventures GP III, L.L.C. | TenPercentOwner | Buy | 253K | $22.00 | $5.6M | 253K |
| 2024-02-12 | Vida Ventures GP III, L.L.C. | TenPercentOwner | Conversion | 4.5M | price not stated in the filing | not stated | 4.5M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON5 Form 144 notices on file for KYTX worth $632K at the prices reported; 0 in the last 90 days worth $0. Latest: KAREN WALKER filed on 2026-04-17 to sell 10,000 shares ($95K) from 2026-04-17.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-04-17 | KAREN WALKEROfficer | 10K | $95K | 0.017% | 2026-04-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-14 | KAREN WALKEROfficer | 2K | $23K | 0.004% | 2026-04-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-07 | DANIEL SPIEGELMANDirector | 18K | $163K | 0.029% | 2026-04-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-31 | DANIEL SPIEGELMANDirector | 17K | $140K | 0.028% | 2026-03-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-15 | KAREN WALKEROfficer | 24K | $211K | 0.055% | 2025-12-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON12 holders report 5% or more of KYTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Dr. Beth C. Seidenberg ("Seidenberg") at 7.8% of the class (4,657,257 shares), filed 2026-02-06 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-19 | 13G | AIGH Capital Management LLCinvestment adviser, other entity | 3.6M | 5.9% | 2026-09-30 |
| 2026-10-19 | 13G | Orin Hirschmanparent holding company, individual | 3.6M | 5.9% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 2 | Bain Capital Life Sciences Opportunities III, LPpartnership | 2.9M | 4.8% | 2026-06-30 |
| 2026-07-29 | 13G | BlackRock, Inc.parent holding company | 3.1M | 5.1% | 2026-06-30 |
| 2026-02-17 | 13G/Ano. 1 | Michael P. Rubinindividual | 3.5M | 6.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Northpond Ventures III, LPpartnership | 2.8M | 4.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Northpond Ventures III GP, LLCother entity | 2.8M | 4.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Northpond Ventures GP, LLCother entity | 450K | 0.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Northpond Ventures, LPpartnership | 450K | 0.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | NPV Listed, LLCother entity | 211K | 0.4% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Northpond Ventures, LLCother entity | 211K | 0.4% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | Dr. Beth C. Seidenberg ("Seidenberg")individual | 4.7M | 7.8% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | Westlake BioPartners GP I, LLC ("Westlake GP I")other entity | 3.8M | 6.3% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | Westlake BioPartners Fund I, L.P. ("Westlake Fund I")partnership | 3.8M | 6.3% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I")other entity | 869K | 1.5% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I")partnership | 869K | 1.5% | 2025-12-31 |
| 2025-11-17 | 13G | Craig D. Gordonparent holding company, individual | 3.1M | 7.0% | 2025-11-13 |
| 2025-11-17 | 13G | GordonMD Global Investments GP LLCparent holding company, other entity | 3.1M | 7.0% | 2025-11-13 |
| 2025-11-17 | 13G | GordonMD Global Investments LPinvestment adviser, partnership | 3.1M | 7.0% | 2025-11-13 |
| 2025-11-17 | 13G | GordonMD Long Biased Master Fund LPpartnership | 2.7M | 6.2% | 2025-11-13 |
| 2025-11-17 | 13G | GordonMD Long Biased GP LLCother entity | 2.7M | 6.2% | 2025-11-13 |
13F holders
Tracked managers holding KYTX at their latest 13F. JSON5 of the 30 tracked managers held KYTX at their latest 13F, $14.6M in total at quarter-end prices. Millennium Management is the largest at $5.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 640K | $5.7M | 0.00% | -366K |
| D. E. Shaw & Co. | 2026-06-30 | 469K | $4.2M | 0.00% | -252K |
| Renaissance Technologies | 2026-06-30 | 334K | $3.0M | 0.00% | -34K |
| Citadel Advisors | 2026-06-30 | 148K | $1.3M | 0.00% | +90K |
| Two Sigma Investments | 2026-06-30 | 51K | $457K | 0.00% | -130K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Kyverna Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Kyverna Therapeutics (KYTX), SEC CIK 1994702, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-04-17.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-19.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-05-27.JSON and CSV
- Company record
- EDGAR filing index for CIK 1994702Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
- SYRESpyre Therapeutics
- SYYSysco
- TAT&T
- TAPMolson Coors
- TCOMTrip.com Group
- TDToronto-Dominion Bank
- TDGTransDigm Group
- TDYTeledyne Technologies
Datasets
Frequently Asked Questions
How much of KYTX is sold short?
9,543,350 shares were held short at the 2026-10-15 settlement, 10.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is KYTX's daily short volume?
On 2026-11-02, 164,732 of the 279,023 KYTX shares reported to FINRA were sold short, 59.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does KYTX have fails to deliver?
The SEC's latest file shows 3,428 KYTX shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are KYTX insiders buying or selling?
No open-market insider trades were reported for KYTX in the last 90 days. The most recent filings are listed below. Latest filing: SEIDENBERG BETH C (Director) on 2026-05-27.
Have KYTX insiders filed to sell?
5 Form 144 notices on file for KYTX worth $632K at the prices reported; 0 in the last 90 days worth $0. Latest: KAREN WALKER filed on 2026-04-17 to sell 10,000 shares ($95K) from 2026-04-17.
Who owns 5% or more of KYTX?
12 holders report 5% or more of KYTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Dr. Beth C. Seidenberg ("Seidenberg") at 7.8% of the class (4,657,257 shares), filed 2026-02-06 for an event on 2025-12-31.
Which tracked 13F managers own KYTX?
5 of the 30 tracked 13F managers held KYTX shares at their latest filing, $14.6M in all. The largest: Izzy Englander's Millennium Management (640K shares, $5.7M), D. E. Shaw & Co. (469K shares, $4.2M), Renaissance Technologies (334K shares, $3.0M), Ken Griffin's Citadel Advisors (148K shares, $1.3M), Two Sigma Investments (51K shares, $457K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.